Rain Therapeutics Inc logo


Rain Therapeutics Inc


Earnings Summary

Net Profits


Net Profits:

Rain Therapeutics Inc’s net profit fell -115.21% since last year same period to $-17.61Mn in the Q2 2022. On a quarterly growth basis, Rain Therapeutics Inc has generated -1.25% fall in its net profits since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Rain Therapeutics Inc post its latest quarter earnings

EPS Estimate Current Quarter
EPS Estimate Current Year


EPS Estimate Current Quarter:

Rain Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.7 - a -25% fall from last quarter’s estimates.

EPS Estimate Current Year:

Rain Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.7.

Key Ratios

Key ratios of the Rain Therapeutics Inc post its Q2 2022 earnings

Return on Assets (ROA)
Return on Equity (ROE)
Dividend Per Share (DPS)


Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Rain Therapeutics Inc’s return on assets (ROA) stands at -0.31.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Rain Therapeutics Inc’s return on equity (ROE) stands at -0.54.

Dividend Per Share (DPS):

Rain Therapeutics Inc declared 0 dividend per share during the earnings announcement for Q2 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %

Company Information

Rain Therapeutics Inc. is a clinical-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. Rain’s lead product candidate, RAIN-32 (milademetan, formerly known as DS-3032), is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to RAIN-32, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.

Rain Therapeutics Inc